This double-blind randomized placebo-controlled trial was designed to investigate the effect of vitamin D3 supplementation on disposition index in non-diabetic Indian subjects with obesity.


Subjects with obesity [n = 120] were randomized to receive a monthly dose of 120000 IU of vitamin D3 or matching placebo for 6 months. Primary outcome was change in disposition index (DI) and secondary outcome measures were change in homeostatic model assessment of insulin resistance and anthropometric parameters.


A total of 101 subjects [50 in vitamin D group (VITD) and 51 in Placebo group (PL)] completed the study. No significant difference was observed between the two groups in any of the primary or secondary outcomes. However, there was significant increase in median serum 25-OH-vitamin D [25(OH) D] levels in the VITD group than the PL at 6 months of intervention.


The results of present study suggest that supplementation of vitamin D3 has no additional benefit over placebo on pancreatic β-cell functions in non-diabetic Indian subjects with obesity. Further larger studies are required to confirm the results of the study.